Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248339 · ClinicalTrials.gov registry record · Phase 3
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection
A Phase 3 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00248339 is a Phase 3 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 150 participants.
The verdict
NCT00248339, a Phase 3 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances at lower viral levels and raising sustained virologic response.
Interventions
- DRUG Ribavirin
- DRUG Peginterferon-alpha-2b (PEG-Intron)
- DRUG Epoetin-alpha (Procrit)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2002-05 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248339
The ClinicalTrials.gov registry entry for NCT00248339 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT00248339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248339 about?
NCT00248339 is a clinical study titled "Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection". The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances at lower viral levels and raising sustained virologic response.
What is the current status of trial NCT00248339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2002-05. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00248339?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon-alpha-2b (PEG-Intron) (DRUG), Epoetin-alpha (Procrit) (DRUG).
Who is sponsoring clinical trial NCT00248339?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.